GlobalData on MSN5d
FDA clears Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini BThe US Food and Drug Administration (FDA) has granted clearance to Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B, ...
Zacks Investment Research on MSN5d
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal PanelQIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...
New QIAstat-Dx Gastrointestinal Panel 2 Mini B adds to QIAGEN’s growing U.S. menu for syndromic testing of gastrointestinal ...
QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...
Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. This marks Qiagen’s second ...
QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...
GERMANTOWN, Md. & VENLO, Netherlands, March 06, 2025--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared ...
The US Food and Drug Administration (FDA) has granted clearance to Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding the company’s syndromic testing offerings in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback